| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2989 | 2019 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1175 | 2018 |
| Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 … K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, ... JAMA oncology 6 (10), 1571-1580, 2020 | 841 | 2020 |
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double … GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ... The Lancet Oncology 20 (8), 1083-1097, 2019 | 701 | 2019 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 453 | 2021 |
| Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. GV Long, R Dummer, O Hamid, T Gajewski, C Caglevic, S Dalle, ... Journal of Clinical Oncology 36 (15_suppl), 108-108, 2018 | 142 | 2018 |
| Immunotherapy in NSCLC: a promising and revolutionary weapon C Rolfo, C Caglevic, M Santarpia, A Araujo, E Giovannetti, CD Gallardo, ... Immunotherapy, 97-125, 2017 | 135 | 2017 |
| KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... Annals of oncology 29, v123, 2018 | 134 | 2018 |
| Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised … MS Carlino, GV Long, D Schadendorf, C Robert, A Ribas, E Richtig, ... European Journal of Cancer 101, 236-243, 2018 | 110 | 2018 |
| Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor proportion score … G de Castro Jr, I Kudaba, YL Wu, G Lopes, DM Kowalski, HZ Turna, ... Journal of clinical oncology 41 (11), 1986-1991, 2023 | 106 | 2023 |
| Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 … CS Fuchs, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandala, MH Ryu, ... Gastric cancer 25 (1), 197-206, 2022 | 98 | 2022 |
| Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial ME Balcells, L Rojas, N Le Corre, C Martínez-Valdebenito, ME Ceballos, ... PLoS medicine 18 (3), e1003415, 2021 | 82 | 2021 |
| The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments LE Raez, AF Cardona, ES Santos, H Catoe, C Rolfo, G Lopes, C Barrios, ... Lung Cancer 119, 7-13, 2018 | 71 | 2018 |
| Immunotherapy in lung cancer: a new age in cancer treatment L Corrales, K Scilla, C Caglevic, K Miller, J Oliveira, C Rolfo Immunotherapy, 65-95, 2018 | 67 | 2018 |
| Oncogenic role of arsenic exposure in lung cancer: A forgotten risk factor C Soza-Ried, E Bustamante, C Caglevic, C Rolfo, R Sirera, H Marsiglia Critical Reviews in Oncology/Hematology 139, 128-133, 2019 | 55 | 2019 |
| Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries LK Sekulovic, J Guo, S Agarwala, A Hauschild, G McArthur, G Cinat, ... European Journal of Cancer 104, 201-209, 2018 | 50 | 2018 |
| Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015 C Rolfo, C Caglevic, D Bretel, D Hong, LE Raez, AF Cardona, AB Oton, ... ESMO open 1 (4), e000055, 2016 | 48 | 2016 |
| Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... Annals of Oncology 32 (9), 1127-1136, 2021 | 44 | 2021 |
| The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer F Passiglia, R Caparica, E Giovannetti, M Giallombardo, A Listi, P Diana, ... Expert opinion on investigational drugs 25 (4), 385-392, 2016 | 43 | 2016 |
| Vaccine and immune cell therapy in non-small cell lung cancer H Oliveres, C Caglevic, F Passiglia, S Taverna, E Smits, C Rolfo Journal of thoracic disease 10 (Suppl 13), S1602, 2018 | 42 | 2018 |
